Back to Search Start Over

Antihypertensive treatment during pregnancy induces long-term changes in gut microbiota and the behaviors of the attention deficit hyperactivity disorder offspring.

Authors :
Li HB
Xu ML
Xia WJ
Dong YY
Peng B
Su Q
Wang XM
Yu JY
Gao YN
Wu JZ
Xu MY
Yang JB
Dai ZM
Chen L
Li Y
Bai J
Source :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2024 May; Vol. 486, pp. 116946. Date of Electronic Publication: 2024 Apr 26.
Publication Year :
2024

Abstract

The pathogenesis of attention-deficit/hyperactivity disorder (ADHD) has not been fully elucidated. Gestational hypertension could double the probability of ADHD in the offspring, while the initial bacterial communication between the mother and offspring has been associated with psychiatric disorders. Thus, we hypothesize that antihypertensive treatment during pregnancy may abate the impairments in neurodevelopment of the offspring. To test this hypothesis, we chose Captopril and Labetalol, to apply to pregnant spontaneously hypertensive rat (SHR) dams and examined the outcomes in the male offspring. Our data demonstrated that maternal treatment with Captopril and Labetalol had long-lasting changes in gut microbiota and behavioral alterations, including decreased hyperactivity and increased curiosity, spatial learning and memory in the male offspring. Increased diversity and composition were identified, and some ADHD related bacteria were found to have the same change in the gut microbiota of both the dam and offspring after the treatments. LC-MS/MS and immunohistochemistry assays suggested elevated expression of brain derived neurotrophic factor (BDNF) and dopamine in the prefrontal cortex and striatum of offspring exposed to Captopril/ Labetalol, which may account for the improvement of the offspring's psychiatric functions. Therefore, our results support the beneficial long-term effects of the intervention of gestational hypertension in the prevention of ADHD.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1096-0333
Volume :
486
Database :
MEDLINE
Journal :
Toxicology and applied pharmacology
Publication Type :
Academic Journal
Accession number :
38679241
Full Text :
https://doi.org/10.1016/j.taap.2024.116946